Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis Would Provide Critical Mass For Sanofi’s Mid-Term R&D – Sanofi CEO

  • News

Executive Summary

Sanofi-Synthelabo's proposed merger with Aventis would provide the critical mass necessary to support the development of Sanofi's early to mid-stage pipeline, CEO Jean-Francois Dehecq said

You may also be interested in...



Sanofi/Aventis Merger Will Not Affect Exubera, Actonel Agreements – Sanofi

Sanofi-Synthelabo does not expect merging with Aventis would negatively affect Aventis' co-promotion agreements for Actonel and Exubera, CEO Jean-Francois Dehecq said during a March 11 investor call

Sanofi/Aventis Merger Will Not Affect Exubera, Actonel Agreements – Sanofi

Sanofi-Synthelabo does not expect merging with Aventis would negatively affect Aventis' co-promotion agreements for Actonel and Exubera, CEO Jean-Francois Dehecq said during a March 11 investor call

Sanofi To Move Two NMEs Into Phase III In 2004, For Total Of Nine

Sanofi-Synthelabo plans to move two new molecular entities into Phase III during 2004

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS043369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By